基于UPLC-Q-Orbitrap/MS技术对非酒精性脂肪性肝病患者的血清脂质组学研究

摘要
图/表
参考文献(26)
相关文章 (15)

全文: PDF (1177 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的基于血清脂质组学研究非酒精性脂肪性肝病（NAFLD）患者的脂质代谢特征。方法将2020年1月至2021年1月上海市普陀区中心医院30例NAFLD患者和30名正常人群纳入研究。采用UPLC-Q-Orbitrap/MS对两组人群血清进行脂质组学分析，使用主成分分析法和正交偏最小二乘法判别分析对数据进行多维统计分析，以VIP值>1、P < 0.05的代谢物为差异性脂质生物标志物。结果两组体重指数，碱性磷酸酶、总蛋白、胆碱酯酶、尿素、甘油三酯比较，差异有统计学意义（P < 0.05）。两组年龄、性别、总胆红素、直接胆红素、白蛋白、γ-谷酰胺转肽酶、丙氨酸转氨酶、天冬氨酸转氨酶、总胆汁酸、肌酐、尿酸、肾小球滤过率、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、总胆固醇比较，差异无统计学意义P > 0.05）。共筛选出181个差异性脂质生物标志物，包括甘油三酯、甘油二酯、鞘磷脂、磷脂酰丝氨酸、磷脂酰胆碱、磷脂酰肌醇、磷脂酰甘油、磷脂酰乙醇胺、O-酰基-ω-羟基脂肪酸、单硬脂酸甘油酯、溶血磷脂酰肌醇、溶血磷脂酰甘油、溶血磷脂乙醇胺、溶血磷脂酰胆碱及神经酰胺等。结论 NAFLD患者的脂质代谢与正常人群有显著差异，本研究筛选出的181个脂质生物标志物可作为潜在的NAFLD的新靶标。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	田继云杜晟楠高静静袁乙富曹勤▲ 蒋元烨▲

关键词 ：非酒精性脂肪性肝病, 脂质组学, UPLC-Q-Orbitrap/MS

Abstract：Objective To study the characteristics of lipid metabolism in patients with non-alcoholic fatty liver disease (NAFLD) based on serum lipidomics. Methods A total of 30 NAFLD patients and 30 normal people in Putuo District Central Hospital of Shanghai from January 2020 to January 2021 were included in the study. UPLC-Q-Orbitrap / MS was used for lipidomics analysis of serum of two groups. Principal component analysis and orthogonal partial least squares discriminant analysis were used for multidimensional statistical analysis of data, metabolites with VIP value >1 and P < 0.05 were used as differential lipid biomarkers. Results There were statistically significant differences in body mass index, alkaline phosphatase, total protein, cholinesterase, urea, and triglyceride between two groups (P < 0.05). There were no significant differences in age, gender, total bilirubin, direct bilirubin, albumin, γ-glutamic transpeptidase, alanine aminotransferase, aspartate aminotransferase, total bile acid, creatinine, uric acid, glomerular filtration rate, high density lipoprotein cholesterol, low density lipoprotein cholesterol, and total cholesterol between two groups (P > 0.05). A total of 181 differential lipid biomarkers were screened, including triglyceride, diglyceride, sphingomyelin, phosphatidylserine, phosphatidylcholines, phosphatidylinositols, phosphatidylglycerides, phosphatidylethanolamines, O-acyl-ω-hydroxy fatty acid, monoglyceride, lysophosphatidylinositol, lysophosphatidylglyceride, lysophosphatidylethanolamine, lysoph- osphatidylcholine, and ceramide. Conclusion Lipid metabolism in NAFLD patients is significantly different from that in the normal population, 181 lipid biomarkers screened in this study can be used as potential new targets for NAFLD.

Key words： Non-alcoholic fatty liver disease Lipido- mics；UPLC-Q-Orbitrap / MS

基金资助:国家自然科学基金青年科学基金项目（81703879）；
上海市卫生和计划生育委员会科研课题（201840377）；
上海市卫生健康委员会科研课题（201940449）；
上海市普陀区卫生健康系统科技创新项目重点项目（ptkwws202201）；
上海中医药大学后备卓越中医人才项目（20D-RC-02）。

通讯作者: ▲共同通讯作者

作者简介: 田继云（1984-），男，硕士，主要从事肝脏及胰腺的相关研究。

引用本文:

田继云杜晟楠高静静袁乙富曹勤▲ 蒋元烨▲. 基于UPLC-Q-Orbitrap/MS技术对非酒精性脂肪性肝病患者的血清脂质组学研究[J]. 中国医药导报, 2022, 19(19): 5-11.
TIAN Jiyun DU Shengnan GAO Jingjing YUAN Yifu CAO Qin▲ JIANG Yuanye▲. Study on serum lipidomics of non-alcoholic fatty liver disease patients based on UPLC-Q-Orbitrap / MS technology. 中国医药导报, 2022, 19(19): 5-11.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I19/5

[1] lmakki E，Aqeely H，Bani I，et al. Nonalcoholic Fatty Liver Diseas（NAFLD）in Saudi Patients with T2DM in Jazan Region：Prevalence and Associated Factors [J]. Br J Med Med Res，2015，5（7）：872-879.
[2] Day CP，James OF. Steatohepatitis：a tale of two“hits”？[J]. Gastroenterology，1998，114（4）：842-845.
[3] Castera L，Friedrich-Rust M，Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease [J]. Gastroenterology，2019，156（5）：1264-1281.
[4] Jarvis H，Craig D，Barker R，et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease（NAFLD）：A systematic review and meta-analysis of population-based observational studies [J]. PLoS Med，2020，17（4）：e1003100.
[5] Stols-Gon?觭alves D，Hovingh GK，Nieuwdorp M，et al. NAFLD and Atherosclerosis：Two Sides of the Same Dysmetabolic Coin？ [J]. Trends Endocrinol Metab，2019，30（12）：891-902.
[6] Han X，Gross RW. Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry：a bridge to lipidomics [J]. J Lipid Res，2003，44（6）：1071-1079.
[7] Lagarde M，Gélo?觕n A，Record M，et al. Lipidomics is emerging [J]. Biochim Biophys Acta，2003，1634（3）：61.
[8] Masoodi M，Gastaldelli A，Hy?觟tyl?覿inen T，et al. Metabolomics and lipidomics in NAFLD biomarkers and non-invasived iagnostictests [J]. Nat Rev Gastroenterol Hepatol，2021，18（12）：835-856.
[9] 李军祥，陈誩，王允亮.非酒精性脂肪性肝病中西医结合诊疗共识意见（2017年）[J].中国中西医结合消化杂志，2017，25（11）：805-811.
[10] 张声生，李军祥.非酒精性脂肪性肝病中医诊疗专家共识意见（2017）[J].临床肝胆病杂志，2017，33（12）：2270-2274.
[11] Tirosh O. Hypoxic Signaling and Cholesterol Lipotoxicity in Fatty Liver Disease Progression [J]. Oxid Med Cell Longev，2018：2548154.
[12] Feldstein AE，Lopez R，Tamimi TA，et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [J]. J Lipid Res，2010，51（10）：3046-3054.
[13] Pagadala M，Kasumov T，McCullough AJ，et al. Role of ceramides in nonalcoholic fatty liver disease [J]. Trends Endocrinol Metab，2012，23（8）：365-371.
[14] Puri P，Wiest MM，Cheung O，et al. The plasma lipidomic signature of nonalcoholic steatohepatitis [J]. Hepatology，2009，50（6）：1827-1838.
[15] Mendez-Sanchez N，Cruz-Ramon VC，Ramirez-Perez OL，et al. New spects of Lipotoxicity in Nonalcoholic Steatohepatitis [J]. Int J Mol Sci，2018，19（7）：2034.
[16] Puri P，Baillie RA，Wiest MM，et al. A lipidomic analysis of nonalcoholic fatty liver disease [J]. Hepatology，2007， 46（4）：1081-1090.
[17] Gorden DL，Ivanova PT，Myers DS，et al. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease；comparison to a murine model [J]. PLoS One，2011，6（8）：e22775.
[18] Anjani K，Lhomme M，Sokolovska N，et al. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity [J]. J Hepatol，2015，62（4）：905-912.
[19] 张有江，徐勤，袁飞.脂肪肝患者血脂及胆碱酯酶测定的临床意义[J].实验与检验医学，2008，26（5）：5557-5582.
[20] Hu Y，He W，Huang Y，et al. Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD [J]. Hepatology，2021，74（5）：2508-2525.
[21] 杨萍，李秋芳.血清AKP、γ-GT、甲胎蛋白在原发性肝癌患者介入治疗前后的变化及意义[J].中国卫生工程学，2021，20（1）：160-161.
[22] Chan AW，Chan SL，Mo FK，et al. Albumin-to-alkaline phosphatase ratio：a novel prognostic indexf or hepatocellular carcinoma [J]. DisMarkers，2015，2015：564057.
[23] Lemaitre RN，Yu C，Hoofnagle A，et al. Circulating Sphingolipids，Insulin，HOMA-IR，and HOMA-B：The Strong Heart Family Study [J]. Diabetes，2018，67（8）：1663-1672.
[24] 杨蕊旭，胡春秀，宓余强，等.非酒精性脂肪性肝病患者血清脂质组学研究[J].中华肝脏病杂志，2017，25（2）：122-127.
[25] Tu LN，Showalter MR，Cajka T，et al. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice [J]. Sci Rep，2017，27（1）：6120.
[26] Casta?觡o D，Rattanasopa C，Monteiro-Cardoso VF，et al. Lipid efflux mechanisms，relation to disease and potential therapeutic aspects [J]. Adv Drug Deliv Rev，2020，159：54-93.